TICKERNERD
Menu
DRIODRIOHealthcare · Health Information Services

DRIO Stock Forecast: DarioHealth Corp. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$7.20
+3.00% on the day

The 5 Wall Street analysts covering DarioHealth Corp. hold a median 12-month price target of $10 — +38.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 19 Sept 2026 — in the upper half.

Market cap
$68.5M
Ticker Nerd rank
51 / 100
Median analyst target
$10
Analysts covering
5
Revenue$5.2M−3.6% y/y
Operating income−$6.5M
Net income−$7.9M
Free cash flow−$6.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.9%
1M
+0.3%
YTD
−36.7%
1Y
+16.7%
From 52W high
−58.5%
From 52W low
+20.2%
$6
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DRIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DarioHealth Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
83
Size
79
Growth
74
Volatility
60
Revisions
54
Quality
48
Momentum
36
Value
27
Issuance
15

Accruals (83): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (15): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DRIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DRIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26DRIOHigh $28Median $10Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $8Median $10High $28

The green dot is the last close — the median target sits +38.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Aug 2026Alliance Global PartnersInitiatesBuy$12
12 Aug 2026TD CowenMaintainsHold$11 → $8.00
14 May 2026StifelReiteratesBuy$10
14 May 2026StifelReiteratesBuy—
13 May 2026TD CowenMaintainsHold$11
13 May 2026TD CowenMaintainsHold—
20 Mar 2026StifelMaintainsBuy—
19 May 2025Litchfield HillsInitiatesBuy—
11 Mar 2025StifelMaintainsBuy—
1 Apr 2024StifelMaintainsBuy—
11 Aug 2023Alliance Global PartnersMaintainsBuy—
25 July 2023StifelMaintainsBuy—
12 May 2023Craig-HallumMaintainsBuy—
16 Nov 2022Alliance Global PartnersMaintainsBuy—
18 Aug 2022Aegis CapitalMaintainsBuy—
16 Aug 2022Cowen & Co.MaintainsOutperform—
16 May 2022Aegis CapitalMaintainsBuy—
16 May 2022Cowen & Co.MaintainsOutperform—
13 May 2022Alliance Global PartnersUpgradeBuy—
26 Jan 2022Aegis CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DRIO appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DRIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, DarioHealth Corp. returned +16.7% against +16.3% for the S&P 500, dividends included.

DRIO vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26DRIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DRIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

DarioHealth Corp. (DRIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.7×

Cheaper than 81% of US stocks

Price / sales
3.3×

Cheaper than 38% of US stocks

Price / book
0.9×

Cheaper than 75% of US stocks

EV / EBITDA
−2.9×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
−3.6%

Higher than 22% of US stocks

Earnings growth (YoY)
−3.6%

Higher than 32% of US stocks

Gross margin
61.7%

Higher than 75% of US stocks

Operating margin
−125.2%

Higher than 12% of US stocks

Net margin
−169.9%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−59.9%

Higher than 19% of US stocks

Return on assets
−19.4%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

DarioHealth Corp. (DRIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • DarioHealth Corp. has a market value of $68.5M and an enterprise value of $87.0M.

  • Revenue in the twelve months to 30 June 2026: $21.0M. The latest quarter shrank 3.6% year on year.

  • Net income over the same four quarters: −$35.7M, a −169.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$25.5M.

  • Shares outstanding: 7.3M.

  • Trailing P/E: −0.7×; forward P/E: −6.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • DarioHealth Corp. employs 160 people — $131K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Sept 2026

Data provided by Twelve Data

Peers

DRIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
DRIODarioHealth Corp.$68.5M
51
CCLDCareCloud, Inc.$92.2M
72
ONMDOneMedNet Corp.$41.5M
15
HCATHealth Catalyst, Inc.$134.7M
50
OPRXOptimizeRx Corp.$135.3M
81
DHDefinitive Healthcare Corp.$137.0M
77
LFMDLifeMD, Inc.$155.0M
31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own DarioHealth Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DRIO news & analysis

Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives

PRNewsWire · 17 Sept 2026positive

DarioHealth announced a new contract with one of New Jersey's largest health plans, representing approximately 1.5 million covered lives. The agreement, secured through channel partner Amwell, covers Dario's cardiometabolic suite and provider-backed care, with revenue expected to begin in the first quarter of 2027.

Why it matters — This is the third large state health plan signed through Amwell in the past 12 months, following contracts in Arizona and Florida, significantly expanding Dario's reach through its channel distribution strategy.

DarioHealth Corp. (DRIO) Q2 2026 Earnings Call Transcript

Seeking Alpha · 11 Aug 2026neutral

DarioHealth Corp. held its Q2 2026 earnings call, and Seeking Alpha published the corresponding transcript of the event. The call covers the company's second-quarter 2026 financial results and commentary.

Why it matters — DRIO watchers would review this transcript for management's discussion of the company's Q2 2026 performance and outlook.

DarioHealth Q2 Earnings Call Highlights

MarketBeat · 11 Aug 2026neutral

DarioHealth reported second-quarter 2026 revenue of $5.2 million, down from $5.6 million in the prior quarter and $5.4 million a year earlier. The decline reflects the company's continued shift away from pharmaceutical services revenue toward recurring B2B2C business.

Why it matters — DRIO watchers would track the quarterly revenue decline and the company's ongoing transition to recurring B2B2C revenue as it reshapes its business mix.

DarioHealth Corp. (DRIO) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 11 Aug 2026positive

DarioHealth Corp. reported a second-quarter loss of $0.57 per share, narrower than the Zacks Consensus Estimate of a $0.76 loss and an improvement from the $2.40 per share loss a year earlier.

Why it matters — A DRIO watcher would care because the company beat consensus loss estimates and narrowed its year-over-year loss, indicating improving quarterly financial performance.

DarioHealth Reports Second Quarter 2026 Financial Results

PRNewsWire · 11 Aug 2026positive

DarioHealth reported second-quarter 2026 revenue of $5.2 million, with gross margin rising to 62% and operating loss down 30% year-over-year. The company highlighted commercial momentum including a top-5 national health plan expansion, and completed an at-the-market financing raising $22.8 million in net proceeds.

Why it matters — The results show improving margins and cost discipline alongside multi-condition revenue growth and expanded commercial distribution, which are key drivers for DarioHealth investors to track.

FAQ

Frequently asked questions about DRIO stock

What is the DRIO stock price forecast for 2026-2027?

The 5 Wall Street analysts covering DarioHealth Corp. have a median 12-month price target of $10, with estimates ranging from $8 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DRIO stock a buy right now?

Of the 5 analysts covering DarioHealth Corp., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DarioHealth Corp. 51 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DRIO?

As at 19 Sept 2026, DarioHealth Corp. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (83 of 100).

Will DRIO stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +38.9% from the last close, and Ticker Nerd's factor model ranks DarioHealth Corp. 51 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DRIO stock forecast for 2030?

No analyst covering DarioHealth Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DRIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $28 over the next 12 months.

How has DRIO stock performed over the past year?

DarioHealth Corp. returned +16.7% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DarioHealth Corp. do?

DarioHealth Corp. is a digital health company that provides connected, data-driven solutions for chronic condition management.

What is the latest news on DRIO?

The most recent item we track (PRNewsWire, 17 Sept 2026): "Dario Wins Contract with One of New Jersey's Largest Health Plans Representing 1.5 Million Covered Lives". DarioHealth announced a new contract with one of New Jersey's largest health plans, representing approximately 1.5 million covered lives. The agreement, secured through channel partner Amwell, covers Dario's cardiometabolic suite and provider-backed care, with revenue expected to begin in the first quarter of 2027.

Company

About DarioHealth Corp.

DarioHealth Corp. is a digital health company that provides connected, data-driven solutions for chronic condition management. DarioHealth focuses on supporting people living with diabetes, hypertension, weight management needs, musculoskeletal pain, and behavioral health conditions through its integrated digital therapeutics platform. Its offerings combine mobile software, connected monitoring devices, personalized interventions, and live coaching to deliver ongoing support between clinical visits. The company’s product suite includes solutions for metabolic health, musculoskeletal care, behavioral health, and broader chronic condition management, serving health plans, employers, providers, and consumers across multiple markets. DarioHealth Corp. plays a role in the healthcare technology sector by helping make chronic care more accessible, personalized, and scalable through software-based care delivery and remote monitoring tools.

CEO Mr. Erez Raphael · 160 employees · United States · https://www.dariohealth.com